Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ADH1A | P07327 | 2/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | ADH1C | P00326 | 1/20 | 0.33 |
| ▸ | PYGL | P06737 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13472120 | 0.85 | HSD11B1 (0.36) | HSD11B1L3MBTL1MEN1KMT2ADPP4 | |
| SCHEMBL12200780 | 0.76 | ALDH1A1 (0.44) | MEN1KMT2AADH1AADH1C | |
| SCHEMBL13612711 | 0.76 | ALDH1A1 (0.44) | L3MBTL1MEN1KMT2AADH1APYGL | |
| SCHEMBL9812911 | 0.75 | PIK3CD (0.40) | L3MBTL1MEN1KMT2AADH1APYGL | |
| SCHEMBL13887673 | 0.75 | HSD11B1 (0.35) | HSD11B1L3MBTL1MEN1KMT2ADPP4 | |
| SCHEMBL12788602 | 0.75 | ADH1A (0.44) | HSD11B1L3MBTL1MEN1KMT2AADH1A | |
| SCHEMBL1067463 | 0.74 | EPHX1 (0.36) | HSD11B1L3MBTL1DPP4PYGL | |
| SCHEMBL1062922 | 0.73 | AGER (0.39) | L3MBTL1PYGL | |
| SCHEMBL19477968 | 0.72 | L3MBTL1 (0.39) | HSD11B1L3MBTL1MEN1KMT2AADH1A | |
| SCHEMBL10323856 | 0.72 | CA14 (0.34) | HSD11B1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592349-B2 | Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors | IRM LLC (BM) | 2009-09-22 | — | — | US | disclosed |
| US-20080139559-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY (BM) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139559-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | KIT, PRKCH, PRKCE | HSD11B1 4147/4885L3MBTL1 4630/4885MEN1 2421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.